| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12282-016-0677-4 |
| P698 | PubMed publication ID | 26874836 |
| P2093 | author name string | Tetsuya Taguchi | |
| Hiroshi Koyama | |||
| Kei Yamada | |||
| Akio Yanagisawa | |||
| Eiichi Konishi | |||
| Akiko Okamoto | |||
| Ikuya Fujiwara | |||
| Naruhiko Mizuta | |||
| Aya Imai | |||
| Yoshifumi Fujita | |||
| Yayoi Kadotani | |||
| Mariko Goto | |||
| Kenichirou Fukuda | |||
| Midori Morita | |||
| Kouichi Sakaguchi | |||
| Katsuhiko Nakatsukasa | |||
| Yoshimi Oouchi | |||
| Asako Hamaoka | |||
| Takayuki Matsuda | |||
| Tatsuya Kotani | |||
| Sadao Kawakami | |||
| Mari Soushi | |||
| Seiichi Imanishi | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 | ||
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 | ||
| Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer | Q35847450 | ||
| Preoperative chemotherapy treatment of breast cancer--a review | Q36973572 | ||
| Docetaxel | Q40434995 | ||
| Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. | Q45985434 | ||
| Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. | Q46127853 | ||
| Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. | Q50773376 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. | Q53256954 | ||
| Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. | Q54244722 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. | Q54544554 | ||
| HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 | ||
| P433 | issue | 1 | |
| P921 | main subject | trastuzumab | Q412616 |
| docetaxel | Q420436 | ||
| P304 | page(s) | 92-97 | |
| P577 | publication date | 2016-02-13 | |
| P1433 | published in | Breast Cancer | Q15752871 |
| P1476 | title | Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer. | |
| P478 | volume | 24 |
| Q58553890 | Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer |
| Q91844555 | Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study |
| Q52626663 | Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. |
Search more.